Oral Peptides Guide

Most peptides require subcutaneous injection because gut proteases destroy them before absorption. But a small subset of peptides are short enough, structurally modified, or targeted at gut tissue specifically — making oral or intranasal administration genuinely effective. This guide covers which oral peptides have scientific rationale, which do not, and what to expect from injection-free peptide protocols.

Peptides are chains of amino acids linked by peptide bonds — and the GI tract evolved specifically to break those bonds. Pepsin in the stomach cleaves peptide bonds at aromatic residues, while trypsin and chymotrypsin in the small intestine further digest protein fragments into individual amino acids. A 15-amino-acid peptide like BPC-157 faces near-total destruction before it can reach intestinal epithelium, let alone systemic circulation.

The exception is very short peptides (di- and tripeptides) that can be absorbed via PepT1 transporters in the intestinal epithelium. KPV (Lys-Pro-Val) — a 3-amino acid fragment of alpha-MSH — is small enough to survive gut transit and be absorbed intact, which is why it has demonstrated oral anti-inflammatory activity in IBD models. Larazotide (8 amino acids) is another exception — it acts locally in the gut lumen without requiring systemic absorption to produce its tight junction-stabilizing effects.

BPC-157 arginine salt is a special case — the arginine conjugation appears to protect the peptide from gastric degradation and may facilitate mucosal absorption, explaining why animal studies show oral BPC-157 arginine salt produces gut-healing effects comparable to the injectable form for GI-targeted applications. For systemic effects (tendon healing, CNS), subcutaneous BPC-157 retains superiority.